ProLung, Inc. Appoints Mark Anderson, CPA as Chief Financial Officer
March 28, 2018
SALT LAKE CITY, UT / ACCESSWIRE / March 28, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules. Today ProLung announces the appointment of Mark V. Anderson, CPA as Chief Financial Officer.
Steven Eror, President and CEO of ProLung stated, ''I am pleased to welcome Mark as our Chief Financial Officer. With more than twenty years in public accounting and experience with complex Securities and Exchange Commission (SEC) filings, he is well-suited to elegantly address the financial and regulatory requirements for our publicly reporting company. The addition of Mark to our team elevates the financial leadership at ProLung, which will ultimately benefit our shareholders.''
Before joining ProLung, Mr. Anderson was most recently a partner with Eide Bailly LLP and previously a partner with Hansen, Barnett and Maxwell which was acquired by Eide Bailly LLP. His roles included Quality Control Director and Engagement Partner for various public and private companies in healthcare and other industries. Mr. Anderson is currently the Chairman of the Accounting and Audit Issues Committee for the Utah Association of CPA's.
Mr. Anderson is a Certified Public Accountant. He holds both a Bachelor of Science and a Masters of Professional Accountancy degree from Weber State University.
About ProLung, Inc.
ProLung's mission is to make a difference in time for lung cancer patients. ProLung is the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules that can lead to lung cancer. The Company develops, tests, and commercializes solutions which is designed to accelerate the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung's predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and investigational use in the USA.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the Company, expressed by such language as ''expected,'' ''anticipated,'' ''projected'' and ''forecasted.'' Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the Company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.
For further information, contact:
Andy Robertson | +1 801-503-9231| email@example.com
ProLung Chief Marketing Officer
757 E. South Temple Suite 150
Salt Lake City, Utah 84102
SOURCE: ProLung, Inc.
Read more: http://www.digitaljournal.com/pr/3713803#ixzz5B5JFoXN2